Compare ASC & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASC | KALV |
|---|---|---|
| Founded | 2010 | N/A |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.9M | 1.0B |
| IPO Year | 2013 | 2014 |
| Metric | ASC | KALV |
|---|---|---|
| Price | $15.98 | $26.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $17.00 | ★ $32.60 |
| AVG Volume (30 Days) | 713.6K | ★ 3.9M |
| Earning Date | 05-07-2026 | 07-09-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | N/A | $185.42 |
| Revenue Next Year | N/A | $59.23 |
| P/E Ratio | $16.60 | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $9.18 | $9.83 |
| 52 Week High | $20.03 | $26.85 |
| Indicator | ASC | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 34.47 | 74.29 |
| Support Level | $14.91 | $14.22 |
| Resistance Level | $16.91 | $26.85 |
| Average True Range (ATR) | 0.73 | 0.06 |
| MACD | -0.43 | -0.28 |
| Stochastic Oscillator | 6.64 | 76.47 |
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The company markets its services directly to its customers and commercial pool operators and charters its vessels to them through a combination of spot, commercial pooling, and time-charter arrangements. The majority of its revenue is generated from spot voyages, which typically last less than three months.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.